Literature DB >> 26962087

In Vitro Antimicrobial Susceptibility of Staphylococcus pseudintermedius Isolates of Human and Animal Origin.

Romney M Humphries1, Max T Wu2, Lars F Westblade3, Amy E Robertson4, Carey-Ann D Burnham5, Meghan A Wallace5, Eileen M Burd6, Sara Lawhon7, Janet A Hindler8.   

Abstract

MIC results for 115 Staphylococcus intermedius group isolates are presented. Of these, 33% were methicillin resistant, among which 51.4% were susceptible to doxycycline, 29.7% to clindamycin, and 21.6% to trimethoprim-sulfamethoxazole. All of the isolates were susceptible to ceftaroline, daptomycin, linezolid, nitrofurantoin, quinupristin-dalfopristin, rifampin, tigecycline, and vancomycin. Of all the isolates, 82.6%, 67.8%, and 23.5% were susceptible to ciprofloxacin, erythromycin, and penicillin, respectively. No isolates harbored mupA or qacA/B genes, which suggested a lack of resistance to mupirocin or chlorhexidine.
Copyright © 2016, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26962087      PMCID: PMC4844724          DOI: 10.1128/JCM.00270-16

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  21 in total

1.  Incidence of inducible clindamycin resistance in Staphylococcus pseudintermedius from dogs.

Authors:  Randi M Gold; Sara D Lawhon
Journal:  J Clin Microbiol       Date:  2013-09-11       Impact factor: 5.948

2.  Improved detection of Staphylococcus intermedius group in a routine diagnostic laboratory.

Authors:  John Lee; Aimee Murray; Richard Bendall; William Gaze; Lihong Zhang; Michiel Vos
Journal:  J Clin Microbiol       Date:  2014-12-10       Impact factor: 5.948

3.  Staphylococcus pseudintermedius can be misdiagnosed as Staphylococcus aureus in humans with dog bite wounds.

Authors:  S Börjesson; E Gómez-Sanz; K Ekström; C Torres; U Grönlund
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2014-12-23       Impact factor: 3.267

4.  Contemporary tetracycline susceptibility testing: doxycycline MIC methods and interpretive criteria (CLSI and EUCAST) performance when testing Gram-positive pathogens.

Authors:  Ronald N Jones; Matthew G Stilwell; Michael L Wilson; Rodrigo E Mendes
Journal:  Diagn Microbiol Infect Dis       Date:  2013-03-13       Impact factor: 2.803

5.  Evaluation of canine-specific minocycline and doxycycline susceptibility breakpoints for meticillin-resistant Staphylococcus pseudintermedius isolates from dogs.

Authors:  Melanie L Hnot; Lynette K Cole; Gwendolen Lorch; Mark G Papich; Paivi J Rajala-Schultz; Joshua B Daniels
Journal:  Vet Dermatol       Date:  2015-07-28       Impact factor: 1.589

6.  Pharmacodynamics of doxycycline and tetracycline against Staphylococcus pseudintermedius: proposal of canine-specific breakpoints for doxycycline.

Authors:  Marit Gaastra Maaland; Mark G Papich; John Turnidge; Luca Guardabassi
Journal:  J Clin Microbiol       Date:  2013-08-21       Impact factor: 5.948

7.  Evaluation of minocycline susceptibility of methicillin-resistant Staphylococcus pseudintermedius.

Authors:  J S Weese; K Sweetman; H Edson; J Rousseau
Journal:  Vet Microbiol       Date:  2012-10-11       Impact factor: 3.293

8.  Prevalence of mupirocin resistance in Staphylococcus pseudintermedius.

Authors:  Stacey M Godbeer; Randi M Gold; Sara D Lawhon
Journal:  J Clin Microbiol       Date:  2014-01-29       Impact factor: 5.948

9.  Activities of vancomycin, ceftaroline, and mupirocin against Staphylococcus aureus isolates collected in a 2011 national surveillance study in the United States.

Authors:  Sandra S Richter; Daniel J Diekema; Kristopher P Heilmann; Cassie L Dohrn; Emily K Crispell; Fathollah Riahi; Jennifer S McDanel; Sarah W Satola; Gary V Doern
Journal:  Antimicrob Agents Chemother       Date:  2013-11-18       Impact factor: 5.191

10.  Genomic insights into the rapid emergence and evolution of MDR in Staphylococcus pseudintermedius.

Authors:  Alex J McCarthy; Ewan M Harrison; Kinga Stanczak-Mrozek; Bernadette Leggett; Andrew Waller; Mark A Holmes; David H Lloyd; Jodi A Lindsay; Anette Loeffler
Journal:  J Antimicrob Chemother       Date:  2014-12-18       Impact factor: 5.790

View more
  5 in total

1.  Epidemiology, Clinical Characteristics, and Antimicrobial Susceptibility Profiles of Human Clinical Isolates of Staphylococcus intermedius Group.

Authors:  Melanie L Yarbrough; William Lainhart; C A Burnham
Journal:  J Clin Microbiol       Date:  2018-02-22       Impact factor: 5.948

2.  Performance of Five Commercial Identification Platforms for Identification of Staphylococcus delphini.

Authors:  David A Bemis; Karen C Carroll; Lars F Westblade; Matthew C Canver; Tsigereda Tekle; Samantha T Compton; Katrina Callan; Eileen M Burd; Barbara L Zimmer
Journal:  J Clin Microbiol       Date:  2019-10-23       Impact factor: 5.948

3.  Prevalence, Mechanism, Genetic Diversity, and Cross-Resistance Patterns of Methicillin-Resistant Staphylococcus Isolated from Companion Animal Clinical Samples Submitted to a Veterinary Diagnostic Laboratory in the Midwestern United States.

Authors:  Mehmet Cemal Adiguzel; Kayla Schaefer; Trevor Rodriguez; Jessica Ortiz; Orhan Sahin
Journal:  Antibiotics (Basel)       Date:  2022-04-30

4.  Potent, specific MEPicides for treatment of zoonotic staphylococci.

Authors:  Rachel L Edwards; Isabel Heueck; Soon Goo Lee; Ishaan T Shah; Justin J Miller; Andrew J Jezewski; Marwa O Mikati; Xu Wang; Robert C Brothers; Kenneth M Heidel; Damon M Osbourn; Carey-Ann D Burnham; Sophie Alvarez; Stephanie A Fritz; Cynthia S Dowd; Joseph M Jez; Audrey R Odom John
Journal:  PLoS Pathog       Date:  2020-06-04       Impact factor: 6.823

5.  From canines to humans: Clinical importance of Staphylococcus pseudintermedius.

Authors:  Karen C Carroll; Carey-Ann D Burnham; Lars F Westblade
Journal:  PLoS Pathog       Date:  2021-12-02       Impact factor: 6.823

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.